The group’s principle activity is to develop innovative immunotherapies designed to optimize the functions of the immune systems T and B cells for the tratment and prevention of cancer and infectious disease. The group’s technologies include antigen presenting cells, antigen presentation, and Mithravax(TM). The group operates from United States.
